A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

A Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 With Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer

This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer.

Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.

Study Overview

• Status: Terminated
• Conditions: Pancreatic Cancer
• Intervention / Treatment: Drug: MRx0518; Radiation: Hypofractionated Preoperative Radiation

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient has signed informed consent and is willing to comply with the protocol
• Cytologic or biopsy confirmed adenocarcinoma of the pancreas
• TNM stage: Tx, T1-4, N0-1 or Nx, M0
• Potentially resectable pancreatic cancer defined as no extra-pancreatic disease, no evidence of tumor extension to the celiac axis, common hepatic artery and superior mesenteric artery, and no evidence of deformity of the superior mesenteric vein or superior mesenteric portal vein confluence
• No evidence of distant metastases either prior to or after induction chemotherapy
• Able to comply with instructions required for radiation therapy
• Age 18 years or older
• Completion of 2-6 months of standard induction chemotherapy (mFOLFIRINOX, gemcitabine and nab-paclitaxel or other)
• Eastern Cooperative Oncology Group Score 0, 1 or 2
• Adequate haematologic function (absolute neutrophil count ≥1500mm3; haemoglobin ≥8.0 g/dL; platelet count ≥50000mm3)
• Adequate renal and liver function (creatinine ≤ 1.5 x upper limit of normal; total bilirubin ≤ 1.5 x upper limit of normal; aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal; alkaline phosphatase ≤ 2.5 x upper limit of normal

Exclusion Criteria:

• Prior radiation therapy to the abdomen that would overlap with the treatment field
• Prior surgical resection of pancreatic tumor
• Receiving any approved or investigational anti-cancer agent other than those provided for in this study
• Uncontrolled or active gastric or duodenal ulcer disease within 30 days of dosing
• Residual or ongoing ≥Grade 3 toxicity from chemotherapy
• Contraindication to IV contrast that can't be managed with pre-medication
• Concurrent participation in another interventional clinical trial or use of another investigational agent within 30 days of consent (concurrent non-interventional trials are eligible)
• Uncontrolled intercurrent illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia, stroke, or psychiatric illness that would limit compliance with treatment
• Second primary malignancy within the last 5 years, unless treated definitively and/or low risk in the judgement of the treating investigator
• Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have history of infection are eligible)
• Known intolerance or hypersensitivity to study drug
• Subjects who are allergic to amoxicillin/clavulanic acid, erythromycin and imipenem
• Female subjects who are breastfeeding
• Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control for the entire study and for 30 days after last dose of MRx0518. A negative pregnancy test must be obtained within 14 days prior to start of treatment
• Male subjects who are unwilling or unable to use an acceptable method of birth control for the entire study period and for 30 days after last dose of MRx0518
• Serious infection requiring systemic therapy
• Use of systemic antibiotics within 2 weeks of start of study treatment
• Has a known inability for intake of oral capsules

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MRx0518 with hypofractionated preoperative radiation; Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.	Drug: MRx0518; MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.; Radiation: Hypofractionated Preoperative Radiation; Radiation will be delivered as 30Gy/10 fractions over two weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events	Adverse events will be assessed as per CTCAE v5.0	Up to 1 year post completion of radiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major pathologic response	Major pathologic response is defined as <5% viable cells in resected tumour specimen	At time of surgery
Tumour infiltrating lymphocytes (TILs)	Changes in TILs from optional baseline biopsy to resected tumour specimen will be assessed.	Baseline to Surgery
Overall Survival (OS)	OS is defined as the duration from the start of study treatment until death due to any cause	12 months post radiation
Progression Free Survival (PFS)	PFS is defined as the duration from the start of study treatment until disease progression or death	12 months post radiation
Local Control	Local control is defined as absence of progression at the primary site and will be assessed with imaging	6 months post radiation
Distant Control	Distant control is defined as absence of progression at any site other than the primary site and will be assessed with imaging	6 months post radiation
Margin status	The margin status of the tumour at the time of surgery will be assessed	At time of surgery

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes to microbiome	The microbiome profile of faecal, urine, tumour and duodenum samples will be analysed for changes using the MicroDx platform	Baseline to 6 months post completion of radiation
Tumour immune infiltration	Optional biopsies and resection specimens will be assessed for changes in tumour immune infiltrates	Baseline to Surgery
Landscape of immune and stromal cells	Optional biopsy and resection specimens will be catalogued for the landscape of immune and stromal cells	Baseline to Surgery
Changes in Circulating Tumour Cells	Blood samples will be assessed for presence of circulating tumour cells, circulating tumour DNA and/or circulating immune cells	Baseline to 6 months post completion of radiation
Genomic changes	Whole exome sequencing and transcriptome sequencing from tumour and blood samples will be performed	Baseline to 6 months post completion of radiation

Collaborators and Investigators

• Sponsor: 4D pharma plc
• Investigators: Principal Investigator: Cullen M Taniguchi, MD, M.D. Anderson Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2019
• Primary Completion (Actual): May 8, 2023
• Study Completion (Actual): May 8, 2023

Study Registration Dates

• First Submitted: November 12, 2019
• First Submitted That Met QC Criteria: December 6, 2019
• First Posted (Actual): December 10, 2019

Study Record Updates

• Last Update Posted (Estimated): June 2, 2023
• Last Update Submitted That Met QC Criteria: June 1, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: MRx0518-I-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No